S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
CVS Health Corporation Is Coiled And Ready To Spring Higher 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Daqo New Energy Charged Up For New Highs
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
TG Therapeutics Stock 300% Rally Has Legs Yet
How major US stock indexes fared Wednesday 2/7/2023
Profit From the Commercial Solar Boom? (Ad)
No Spice In Chipotle Results, Is Now The Time To Buy?
Fortinet’s Earnings Rally is a Lesson in Market Expectations
NASDAQ:ONTX

Onconova Therapeutics - ONTX Stock Forecast, Price & News

$1.28
-0.06 (-4.48%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.27
$1.49
50-Day Range
$0.63
$1.42
52-Week Range
$0.62
$2.04
Volume
491,573 shs
Average Volume
412,288 shs
Market Capitalization
$26.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Onconova Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
603.1% Upside
$9.00 Price Target
Short Interest
Healthy
0.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Onconova Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.91) to ($0.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

243rd out of 1,026 stocks

Pharmaceutical Preparations Industry

110th out of 504 stocks

ONTX stock logo

About Onconova Therapeutics (NASDAQ:ONTX) Stock

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Stock News Headlines

YIKES! 220 Pounds of Graphite in Each EV Battery?
Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.
Onconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.com
YIKES! 220 Pounds of Graphite in Each EV Battery?
Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.
ONTX.O - | Stock Price & Latest News | Reuters
ONTX Onconova Therapeutics, Inc.
See More Headlines
Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Company Calendar

Last Earnings
11/14/2022
Today
2/08/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONTX
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+446.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-16,160,000.00
Net Margins
-7,658.41%
Pretax Margin
-7,658.41%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$2.22 per share

Miscellaneous

Free Float
20,645,000
Market Cap
$26.75 million
Optionable
Not Optionable
Beta
1.81

Key Executives

  • Steven M. FruchtmanSteven M. Fruchtman
    President, Chief Executive Officer & Director
  • Mark P. Guerin
    Chief Operating & Financial Officer
  • Matthew Parris
    Vice President-Clinical Operations
  • Mark Stephen Gelder
    Chief Medical Officer
  • Adar Makovski Silverstein
    Senior Director & Head-Corporate Development













ONTX Stock - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings
or view top-rated stocks.

What is Onconova Therapeutics' stock price forecast for 2023?

2 brokerages have issued 12 month target prices for Onconova Therapeutics' shares. Their ONTX share price forecasts range from $7.00 to $11.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 603.1% from the stock's current price.
View analysts price targets for ONTX
or view top-rated stocks among Wall Street analysts.

How have ONTX shares performed in 2023?

Onconova Therapeutics' stock was trading at $0.6457 at the beginning of 2023. Since then, ONTX stock has increased by 98.2% and is now trading at $1.28.
View the best growth stocks for 2023 here
.

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our ONTX earnings forecast
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 43.20% and a negative net margin of 7,658.41%.

When did Onconova Therapeutics' stock split?

Onconova Therapeutics's stock reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends
.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $1.28.

How much money does Onconova Therapeutics make?

Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $26.75 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-16,160,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681.

This page (NASDAQ:ONTX) was last updated on 2/9/2023 by MarketBeat.com Staff